Radiosurgery effects and adverse effects in symptomatic eloquent brain-located Cavernomas

Simple item page
dc.authoridBERBER, TANJU/0000-0002-4087-4760
dc.authorwosidBERBER, TANJU/T-1170-2018
dc.contributor.authorBerber, Tanju
dc.contributor.authorÇelik, Suat Erol
dc.contributor.authorAksaray, Ferdi
dc.contributor.authorYöney, Adnan
dc.contributor.authorHarmancı, Kemal
dc.contributor.authorTambas, Makbule
dc.contributor.authorYıldırım, Berna Akkuş
dc.contributor.authorYolcu, Ahmet
dc.date.accessioned2023-04-20T08:01:18Z
dc.date.available2023-04-20T08:01:18Z
dc.date.issued2022
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Radyasyon Onkolojisi Ana Bilim Dalı
dc.description.abstractIn this study, the dose schedule efficacy, safety and late adverse effects of stereotactic radiosurgery (SRS) were evaluated for patients with symptomatic cavernomas who were not eligible for surgery and treated with SRS. Between January 2013 and December 2018, 53 patients with cavernomas were treated using SRS with the CyberKnife (R) system. Patients' diseases were deeply located or were in subcortical functional brain regions. In addition to bleeding, 23 (43.4%) patients had epilepsy, 12 (22.6%) had neurologic symptoms and 16 patients (30.2%) had severe headaches. The median volume was 741 (range, 421-1351) mm(3), and the median dose was 15 (range, 14-16) Gy in one fraction. After treatment, six (50%) of 12 patients with neurologic deficits still had deficits. Rebleeding after treatment developed in only two (3.8%) patients. The drug was completely stopped in 14 (60.9%) out of 23 patients who received epilepsy treatment, and the dose of levetiracetam decreased from 2000 mg to 1000 mg in four (17.3%) of nine patients. Radiologically, complete response (CR) was observed in 13 (24.5%) patients, and partial responses (PR) were observed in 32 (60.2%) patients. Clinical response of CR was observed in 30 (56.6%) patients, PR was observed in 16 (30.2%), stable disease (SD) was observed in three (5.7%) and four (7.5%) patients progressed. In conclusion, SRS applied in the appropriate dose schedule may be an effective and reliable method in terms of symptom control and prevention of rebleeding, especially in patients with inoperable cavernomas.
dc.identifier.doi10.1093/jrr/rrac056
dc.identifier.issn0449-3060
dc.identifier.issn1349-9157
dc.identifier.pmid36208871
dc.identifier.scopus2-s2.0-85147045211
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1093/jrr/rrac056
dc.identifier.urihttps://hdl.handle.net/20.500.11776/10861
dc.identifier.wosWOS:000865140700001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorYolcu, Ahmet
dc.language.isoen
dc.publisherOxford Univ Press
dc.relation.ispartofJournal of Radiation Research
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectCavernoma
dc.subjectEpilepsy
dc.subjectHemangioma
dc.subjectSeizures
dc.subjectStereotactic Radiosurgery (Srs)
dc.subjectCerebral Cavernous Malformations (Ccms)
dc.subjectStereotactic Radiosurgery
dc.subjectNatural-History
dc.subjectVascular Malformations
dc.subjectStem
dc.subjectManagement
dc.subjectAngioma
dc.subjectMetaanalysis
dc.subjectHemorrhages
dc.subjectSurgery
dc.titleRadiosurgery effects and adverse effects in symptomatic eloquent brain-located Cavernomas
dc.typeArticle

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
10861.pdf
Size:
713.88 KB
Format:
Adobe Portable Document Format
Description:
Tam Metin / Full Text
Download

Collections

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu